Gastric neuroendocrine tumors: Biology and management

 
This item is provided by the institution :

Repository :
Annals of Gastroenterology
see the original item page
in the repository's web site and access all digital files if the item*
share




2007 (EN)

Gastric neuroendocrine tumors: Biology and management (EN)

Christopoulos, E. Papavassiliou2, C.

Neoplasms may originate from any of the endocrine cells of the gastric wall, most commonly the enterochromaffinlike (ECL) cells of the oxyntic mucosa. In recent years, the increasing number of screening gastroscopies and biopsies, and the widespread application of sophisticated immunohistochemical stains for neuroendocrine markers, have resulted in the frequent detection of ECL tumors. The latter are regarded as a separate clinicopathological entity seen in the setting of hypergastrinemic states, and their pathogenesis follows the sequence “hyperplasia – dysplasia – neoplasia”. According to the most recent WHO classification, gastric neuroendocrine tumors (NETs) are generally divided into “well-differentiated NETs” (class 1a), “welldifferentiated neuroendocrine carcinomas (NECs)” (class 1b) and “poorly differentiated NECs” (class 2). Well-differentiated tumors (NETs and NECs), for which the historic term “carcinoid” is still in use, include three subgroups: Type I (70-80%), associated with chronic atrophic gastritis, which are benign (class 1a) ECL cell tumors in the vast majority of cases; Type II ( (EN)

info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion


English

2007-03-19


Hellenic Society of Gastroenterology (EN)

1792-7463
1108-7471
Annals of Gastroenterology; Volume 18, No 2 (2005) (EN)




*Institutions are responsible for keeping their URLs functional (digital file, item page in repository site)